Treatment and outcome of patients with Graves’ disease and metastatic differentiated thyroid cancer

1. Kahaly GJ. Management of Graves thyroidal and extrathyroidal disease: an update. J Clin Endocrinol Metab 2020; 105: 3704–20. doi: 10.1210/clinem/dgaa646 KahalyGJ Management of Graves thyroidal and extrathyroidal disease: an update J Clin Endocrinol Metab 2020 105 3704 20 10.1210/clinem/dgaa646 Open DOISearch in Google Scholar

2. Smith TJ, Hegedüs L. Graves’ disease. N Engl J Med 2016; 375: 1552–65. doi: 10.1056/NEJMra1510030 SmithTJ HegedüsL Graves’ disease N Engl J Med 2016 375 1552 65 10.1056/NEJMra1510030 Open DOISearch in Google Scholar

3. Mazzaferri EL. Thyroid cancer and Graves’ disease. J Clin Endocrinol Metab 1990; 70: 826–9. doi: 10.1210/jcem-70-4-826 MazzaferriEL Thyroid cancer and Graves’ disease J Clin Endocrinol Metab 1990 70 826 9 10.1210/jcem-70-4-826 Open DOISearch in Google Scholar

4. Mekraksakit P, Rattanawong P, Karnchanasorn R, Kanitsoraphan C, Leelaviwat N, Poonsombudlert K, et al. Prognosis of differentiated thyroid carcinoma in patients with Graves’ disease: a systematic review and meta-analysis. Endocr Pract 2019; 25: 1323–37. doi: 10.4158/EP-2019-0201 MekraksakitP RattanawongP KarnchanasornR KanitsoraphanC LeelaviwatN PoonsombudlertK Prognosis of differentiated thyroid carcinoma in patients with Graves’ disease: a systematic review and meta-analysis Endocr Pract 2019 25 1323 37 10.4158/EP-2019-0201 Open DOISearch in Google Scholar

5. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016; 26: 1–133. doi: 10.1089/thy.2015.0020 HaugenBR AlexanderEK BibleKC DohertyGM MandelSJ NikiforovYE 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer Thyroid 2016 26 1 133 10.1089/thy.2015.0020 Open DOISearch in Google Scholar

6. Filetti S, Durante C, Hartl D, Leboulleux S, Locati LD, Newbold K, et al. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2019; 30: 1856–83. doi: 10.1093/annonc/mdz400 FilettiS DuranteC HartlD LeboulleuxS LocatiLD NewboldK Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 2019 30 1856 83 10.1093/annonc/mdz400 Open DOISearch in Google Scholar

7. Pellegriti G, Mannarino C, Russo M, Leboulleux S, Locati LD, Newbold K, et al. Increased mortality in patients with differentiated thyroid cancer associated with Graves’ disease. J Clin Endocrinol Metab 2013; 98: 1014–21. doi: 10.1210/jc.2012-2843 PellegritiG MannarinoC RussoM LeboulleuxS LocatiLD NewboldK Increased mortality in patients with differentiated thyroid cancer associated with Graves’ disease J Clin Endocrinol Metab 2013 98 1014 21 10.1210/jc.2012-2843 Open DOISearch in Google Scholar

8. Besic N, Vidergar-Kralj B, Zaletel K, Grasic-Kuhar C. Graves’ disease and metastatic hormonal-active Hürthle cell thyroid cancer: a case report. Medicine 2021; 100: e26384. doi: 10.1097/MD.0000000000026384 BesicN Vidergar-KraljB ZaletelK Grasic-KuharC Graves’ disease and metastatic hormonal-active Hürthle cell thyroid cancer: a case report Medicine 2021 100 e26384 10.1097/MD.0000000000026384 Open DOISearch in Google Scholar

9. Sobin L, Gospodarowicz MK, Wittekind C. TNM Classification of Malignant Tumours. 7th edition. Hoboken, USA: John Wiley & Sons; 2009. SobinL GospodarowiczMK WittekindC TNM Classification of Malignant Tumours 7th edition Hoboken, USA John Wiley & Sons 2009 Search in Google Scholar

10. Qiu ZL, Shen CT, Luo QY. Clinical management and outcomes in patients with hyperfunctioning distant metastases from differentiated thyroid cancer after total thyroidectomy and radioactive iodine therapy. Thyroid 2015; 25: 229–37. doi: 10.1089/thy.2014.0233 QiuZL ShenCT LuoQY Clinical management and outcomes in patients with hyperfunctioning distant metastases from differentiated thyroid cancer after total thyroidectomy and radioactive iodine therapy Thyroid 2015 25 229 37 10.1089/thy.2014.0233 Open DOISearch in Google Scholar

11. Liu J, Wang Y, Da D, Zheng M. Hyperfunctioning thyroid carcinoma: a systematic review. Mol Clin Oncol 2019; 11: 535–50. doi: 10.3892/mco.2019.1927 LiuJ WangY DaD ZhengM Hyperfunctioning thyroid carcinoma: a systematic review Mol Clin Oncol 2019 11 535 50 10.3892/mco.2019.1927 Open DOISearch in Google Scholar

12. Girelli ME, Casara D, Rubello D, Pelizzo MR, Busnardo B, Ziliotto D. Severe hyperthyroidism due to metastatic papillary thyroid carcinoma with favorable outcome. J Endocrinol Invest 1990; 13: 333–7. doi: 10.1007/BF03349573 GirelliME CasaraD RubelloD PelizzoMR BusnardoB ZiliottoD Severe hyperthyroidism due to metastatic papillary thyroid carcinoma with favorable outcome J Endocrinol Invest 1990 13 333 7 10.1007/BF03349573 Open DOISearch in Google Scholar

13. Cerletty JM, Listwan WJ. Hyperthyroidism due to functioning metastatic thyroid carcinoma. Precipitation of thyroid storm with therapeutic radioactive iodine. JAMA 1979; 242: 269–70. doi: 10.1001/jama.1979.03300030041020 CerlettyJM ListwanWJ Hyperthyroidism due to functioning metastatic thyroid carcinoma. Precipitation of thyroid storm with therapeutic radioactive iodine JAMA 1979 242 269 70 10.1001/jama.1979.03300030041020 Open DOISearch in Google Scholar

14. Fu H, Cheng L, Jin Y, Chen L. Thyrotoxicosis with concomitant thyroid cancer. Endocr Relat Cancer 2019; 26: R395–413. doi: 10.1530/ERC-19-0129 FuH ChengL JinY ChenL Thyrotoxicosis with concomitant thyroid cancer Endocr Relat Cancer 2019 26 R395 413 10.1530/ERC-19-0129 Open DOISearch in Google Scholar

15. Tan J, Zhang G, Xu W, Meng Z, Dong F, Zhang F, et al. Thyrotoxicosis due to functioning metastatic follicular thyroid carcinoma after twelve I–131 therapies. Clin Nucl Med 2009; 34: 615–9. doi: 10.1097/RLU.0b013e3181b06b2d TanJ ZhangG XuW MengZ DongF ZhangF Thyrotoxicosis due to functioning metastatic follicular thyroid carcinoma after twelve I–131 therapies Clin Nucl Med 2009 34 615 9 10.1097/RLU.0b013e3181b06b2d Open DOISearch in Google Scholar

16. Nishihara E, Amino N, Miyauchi A. Fractionated radioiodine therapy for hyperthyroidism caused by widespread metastatic follicular thyroid carcinoma. Thyroid 2010; 20: 569–70. doi: 10.1089/thy.2009.0460 NishiharaE AminoN MiyauchiA Fractionated radioiodine therapy for hyperthyroidism caused by widespread metastatic follicular thyroid carcinoma Thyroid 2010 20 569 70 10.1089/thy.2009.0460 Open DOISearch in Google Scholar

17. Kunawudhi A, Promteangtrong C, Chotipanich C. A case report of hyperfunctioning metastatic thyroid cancer and rare I–131 avid liver metastasis. Indian J Nucl Med 2016; 31: 210–14. doi: 10.4103/0972-3919.183616. KunawudhiA PromteangtrongC ChotipanichC A case report of hyperfunctioning metastatic thyroid cancer and rare I–131 avid liver metastasis Indian J Nucl Med 2016 31 210 14 10.4103/0972-3919.183616 Open DOISearch in Google Scholar

18. Danilovic DL, de Camargo RY, Castro G Jr, Papadia C, Marui S, Hoff AO, et al. Rapid control of T3 thyrotoxicosis in patients with metastatic follicular thyroid cancer treated with lenvatinib. Thyroid 2015; 25: 1262–4. doi: 10.1089/thy.2015.0167. DanilovicDL de CamargoRY CastroGJr PapadiaC MaruiS HoffAO Rapid control of T3 thyrotoxicosis in patients with metastatic follicular thyroid cancer treated with lenvatinib Thyroid 2015 25 1262 4 10.1089/thy.2015.0167 Open DOISearch in Google Scholar

19. Premoli P, Tanda ML, Piantanida E, Veronesi G, Gallo D, Masiello E, et al. Features and outcome of differentiated thyroid carcinoma associated with Graves’ disease: results of a large, retrospective, multicenter study. J Endocrinol Invest 2020; 43: 109–16. doi: 10.1007/s40618-019-01088-5 PremoliP TandaML PiantanidaE VeronesiG GalloD MasielloE Features and outcome of differentiated thyroid carcinoma associated with Graves’ disease: results of a large, retrospective, multicenter study J Endocrinol Invest 2020 43 109 16 10.1007/s40618-019-01088-5 Open DOISearch in Google Scholar

20. Valenta L, Lemarchand-Béraud T, Nĕmec J, Griessen M, Bednár J. Metastatic thyroid carcinoma provoking hyperthyroidism, with elevated circulating thyrostimulators. Am J Med 1970; 48: 72–6. doi: 10.1016/0002-9343(70)90100-2 ValentaL Lemarchand-BéraudT NĕmecJ GriessenM BednárJ Metastatic thyroid carcinoma provoking hyperthyroidism, with elevated circulating thyrostimulators Am J Med 1970 48 72 6 10.1016/0002-9343(70)90100-2 Open DOISearch in Google Scholar

21. Basaria S, Salvatori R. Thyrotoxicosis due to metastatic papillary thyroid cancer in a patient with Graves’ disease. J Endocrinol Invest 2002; 25: 639–42. doi: 10.1007/BF03345090 BasariaS SalvatoriR Thyrotoxicosis due to metastatic papillary thyroid cancer in a patient with Graves’ disease J Endocrinol Invest 2002 25 639 42 10.1007/BF03345090 Open DOISearch in Google Scholar

22. Als C, Gedeon P, Rösler H, Minder C, Netzer P, Laissue JA, et al. Survival analysis of 19 patients with toxic thyroid carcinoma. J Clin Endocrinol Metab 2002; 87: 4122–7. doi: 10.1210/jc.2001-011147 AlsC GedeonP RöslerH MinderC NetzerP LaissueJA Survival analysis of 19 patients with toxic thyroid carcinoma J Clin Endocrinol Metab 2002 87 4122 7 10.1210/jc.2001-011147 Open DOISearch in Google Scholar

23. Epidemiology and Cancer Registry. Ljubljana: Institute of Oncology Ljubljana. [cited 2019 Aug 28]. Available at: https://www.onko-i.si/eng/sectors/epidemiology-and-cancer-registry Epidemiology and Cancer Registry Ljubljana Institute of Oncology Ljubljana [cited 2019 Aug 28]. Available at: https://www.onko-i.si/eng/sectors/epidemiology-and-cancer-registry Search in Google Scholar